CVRx, Inc. IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on CVRx, Inc., and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| CVRx, Inc. | CVRX - NASDAQ |
$15.00-$17.00 | $18.00 | $26.25 | 7 million | 6/30/2021 |
| JP Morgan, Piper Sandler, William Blair | ||||||
Co-Manager(s): Canaccord Genuity
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-06-04 Terms Added 2021-06-23 | ||||||
CVRx, Inc. Quote & Chart - Click for current quote - CVRX
IPO Boutique aggregates information on public companies and private companies, such as "CVRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About CVRx, Inc. (adapted from CVRx, Inc. prospectus):
They are a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CVRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.